Market revenue in 2020 | USD 35.5 million |
Market revenue in 2028 | USD 79.4 million |
Growth rate | 10.6% (CAGR from 2020 to 2028) |
Largest segment | Oncology |
Fastest growing segment | Personalized Medicine |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Genetic Disorders, Oncology, Personalized Medicine, Other Applications |
Key market players worldwide | Danaher Corp, Abbott Laboratories, Bio-Rad Laboratories Inc, Illumina Inc, Sysmex Corp, Roche Holding AG, BioView, MetaSystems, Agilent Technologies Inc, Revvity Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular cytogenetics market will help companies and investors design strategic landscapes.
Oncology was the largest segment with a revenue share of 39.15% in 2020. Horizon Databook has segmented the Brazil molecular cytogenetics market based on genetic disorders, oncology, personalized medicine, other applications covering the revenue growth of each sub-segment from 2018 to 2028.
Brazil is the leading country in terms of revenue regeneration in Latin America owing to presence of established market players, better medical infrastructure, and increase in research facilities as compared to other countries in the region. Other factors like reforms in healthcare services and various government initiatives are drivers of the market.
Prevalence of chronic diseases is high in Brazil due to moderate standard of living, which increases the need for advanced diagnostics and treatments. According to the World Life expectancy, chronic diseases are major cause of deaths in the country. Hence private and public organizations are undertaking various initiatives to decrease mortality rate.
For instance, in October 2018, Dasa entered into a partnership with Karius, Inc. to introduce Karius’s next-generation sequencing-based infectious disease testing in Brazil. The technology will be available to multiple hospitals in the country to help patients with cancer, HIV/AIDS, and transplant recipients. Moreover, rise in healthcare expenditure in Brazil (around 9.5%) is further anticipated to drive the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil molecular cytogenetics market , including forecasts for subscribers. This country databook contains high-level insights into Brazil molecular cytogenetics market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account